Results 21 to 30 of about 819 (177)
The development of dosage forms necessitates the evaluation of pharmacokinetics and pharmacodynamics (PK/PD), which aids scientists in elucidating the drug's mechanism of action and achieving optimal composite design. The incorporation of pharmacokinetic/pharmacodynamic (PK/PD) efficacy studies in the early phases of lead identification and ...
Yasir Qasim Almajidi +3 more
doaj +2 more sources
Physiologically Based Biopharmaceutics Modeling (PBBM): Best Practices for Drug Product Quality, Regulatory and Industry Perspectives: 2023 Workshop Summary Report. [PDF]
Mackie C +16 more
europepmc +2 more sources
Integrated biopharmaceutical approach in pharmaceutical development and drug characterization: General concept and application [PDF]
The importance of biopharmaceutical considerations in pharmaceutical development and drug characterization has been well recognized both by pharmaceutical industry and regulatory authorities as a tool to establish predictive relationships ...
Cvijić Sandra V. +2 more
doaj +1 more source
Predicting Pharmacokinetics of Multisource Acyclovir Oral Products Through Physiologically Based Biopharmaceutics Modeling [PDF]
Highly variable disposition after oral ingestion of acyclovir has been reported, although little is known regarding the underlying mechanisms. Different studies using the same reference product (Zovirax ®) showed that Cmax and AUC were respectively 44 and 35% lower in Saudi Arabians than Europeans, consistent with higher frequencies of reduced-activity
Mauricio A. García +3 more
openaire +2 more sources
Subcutaneous injection is a commonly used route of drug administration for both small molecules and biologics. To facilitate the development of new subcutaneously administered drugs, methods for prediction of drug absorption from the injection site are essential. For this purpose, in silico models have increasingly been used.
Dubbelboer, Ilse R., Sjögren, Erik
openaire +3 more sources
In the past decade, only a small number of papers have elaborated on the application of physiologically based pharmacokinetic (PBPK) modeling across different areas. In this review, an in-depth analysis of the distribution of PBPK modeling in relation to
Aleksandra Krstevska +3 more
doaj +1 more source
A strategy followed to integrate in vitro solubility and permeability data into a PBBM model to predict the food effect of a BCS IV zwitterionic drug (GSK3640254) observed in clinical studies is described. The PBBM model was developed, qualified and verified using clinical data of an immediate release (IR)-tablet (10–320 mg) obtained in healthy ...
Konstantinos Stamatopoulos +6 more
openaire +3 more sources
Emerging perspectives on leveraging physiologically based biopharmaceutics modeling (PBBM) for BCS class III biowaivers: A webinar summary. [PDF]
The regulatory framework for Biopharmaceutics Classification System (BCS) class III drug products provides a pathway for streamlined biowaivers in drug development, eliminating the need for expensive and time-consuming bioavailability and bioequivalence studies while maintaining quality standards.
Fang L +8 more
europepmc +3 more sources
AbstractPurposeTo construct a detailed mechanistic and physiologically based biopharmaceutics model capable of predicting 1) device-formulation-tissue interaction during the injection process and 2) binding, degradation, local distribution, diffusion, and drug absorption, following subcutaneous injection.
Xavier J. H. Pepin +2 more
openaire +2 more sources
Uprifosbuvir is a uridine nucleoside monophosphate prodrug inhibitor of the hepatitis C virus NS5B RNA polymerase. To quantitatively elucidate key metabolic pathways, assess the link between unmeasurable effect site concentrations and viral load ...
Paul van den Berg +7 more
doaj +1 more source

